FDAmanufacturing / CMC65% confidence
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
Source: FDA
Why This Matters
Why this matters: provides agency context on manufacturing / CMC that may shape timing or evidence expectations for Centaur Pharmaceuticals.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Diabetes · SGLT2 Inhibitor
- Sub-indication
- General
Related signal: Centaur Pharmaceuticals submits ANDA for Dapagliflozin